TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Sep 16, 2021– Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will enhance access to tailored oncology treatments and novel clinical studies for patients receiving care in community oncology practices.

Read the source article at businesswire.com
2021-09-16 01:00:00